{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"44"}],"title":"Male"},{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"36"}],"title":"Female"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"description":"Donor sex","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"},{"description":"Total number of participants","id":"OG002","title":"Total"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Pre-HCT","title":"Donor Selection Characteristics: Donor Sex","type":"SECONDARY","unitOfMeasure":"Participants"}